Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The FDA approved acalabrutinib in combination with venetoclax on 19 February for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval applies to Calquence tablets and capsules with Venclexta. FDA said full prescribing information would be posted through Drugs@FDA.
CLL and SLL treatment has increasingly moved toward targeted combinations designed to control disease while reducing reliance on older chemotherapy approaches.
Sourcing note: The approval and indication are from FDA. This article does not compare regimen sequencing or individual suitability.
Why It Matters
The approval adds another targeted combination to blood-cancer care, where clinicians balance durable control, fixed-duration treatment possibilities, toxicity and patient preference.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAAcalabrutinibVenetoclaxCLLSLL